Merus Bv Stock Performance
| MRUS Stock | USD 95.98 0.10 0.10% |
On a scale of 0 to 100, Merus BV holds a performance score of 11. The company secures a Beta (Market Risk) of 0.58, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Merus BV's returns are expected to increase less than the market. However, during the bear market, the loss of holding Merus BV is expected to be smaller as well. Please check Merus BV's jensen alpha, potential upside, as well as the relationship between the Potential Upside and daily balance of power , to make a quick decision on whether Merus BV's current price movements will revert.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Merus BV are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively conflicting basic indicators, Merus BV unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.0416 | Five Day Return 0.98 | Year To Date Return 127.14 | Ten Year Return 856.97 | All Time Return 856.97 |
1 | Expert Outlook Merus Through The Eyes Of 4 Analysts | 09/29/2025 |
2 | Merus Downgraded to Hold Rating by Wells Fargo Company | 09/30/2025 |
3 | Merus Rating Lowered to Hold at Leerink Partnrs | 10/07/2025 |
4 | Oppenheimer positive on CytomX after Merus colon cancer data CTMXMRUS | 10/14/2025 |
5 | Non-Small Cell Lung Cancer Analysis Report 2025 Market Dominated by Roche, AstraZeneca, Merck, and Novartis, Fueled by Immuno-Oncology, Targeted Therapies, and ... | 10/15/2025 |
6 | HAREHOLDER ALERT The MA Class Action Firm Continues to Investigate Merger - FSFG, MTSR, VRNT, and MRUS | 10/21/2025 |
7 | Merus Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOXFOLFIRI ... | 10/24/2025 |
8 | Disposition of 7300 shares by Harry Shuman of Merus BV at 57.84 subject to Rule 16b-3 | 10/28/2025 |
9 | Halper Sadeh LLC Encourages TIPT, MRUS, PBBK Shareholders to Contact the Firm to Discuss Their Rights | 11/05/2025 |
10 | Merus N.V. Shareholders to Vote on Genmab Acquisition Offer - TipRanks | 11/12/2025 |
| Begin Period Cash Flow | 205 M | |
| Total Cashflows From Investing Activities | -220.2 M |
Merus BV Relative Risk vs. Return Landscape
If you would invest 6,600 in Merus BV on August 16, 2025 and sell it today you would earn a total of 3,008 from holding Merus BV or generate 45.58% return on investment over 90 days. Merus BV is currently generating 0.6865% in daily expected returns and assumes 4.6753% risk (volatility on return distribution) over the 90 days horizon. In different words, 41% of stocks are less volatile than Merus, and 87% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Merus BV Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Merus BV's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Merus BV, and traders can use it to determine the average amount a Merus BV's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1468
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | MRUS | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 4.68 actual daily | 42 58% of assets are more volatile |
Expected Return
| 0.69 actual daily | 13 87% of assets have higher returns |
Risk-Adjusted Return
| 0.15 actual daily | 11 89% of assets perform better |
Based on monthly moving average Merus BV is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Merus BV by adding it to a well-diversified portfolio.
Merus BV Fundamentals Growth
Merus Stock prices reflect investors' perceptions of the future prospects and financial health of Merus BV, and Merus BV fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Merus Stock performance.
| Return On Equity | -0.52 | ||||
| Return On Asset | -0.27 | ||||
| Operating Margin | (7.94) % | ||||
| Current Valuation | 6.67 B | ||||
| Shares Outstanding | 75.85 M | ||||
| Price To Earning | (4.47) X | ||||
| Price To Book | 9.41 X | ||||
| Price To Sales | 128.74 X | ||||
| Revenue | 34.88 M | ||||
| Gross Profit | 20.94 M | ||||
| EBITDA | (260.24 M) | ||||
| Net Income | (215.33 M) | ||||
| Cash And Equivalents | 376.11 M | ||||
| Cash Per Share | 8.20 X | ||||
| Total Debt | 9.91 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 6.62 X | ||||
| Book Value Per Share | 10.22 X | ||||
| Cash Flow From Operations | (185.84 M) | ||||
| Earnings Per Share | (5.28) X | ||||
| Market Capitalization | 7.29 B | ||||
| Total Asset | 785.13 M | ||||
| Retained Earnings | (968.39 M) | ||||
| Working Capital | 482 M | ||||
| Current Asset | 68 M | ||||
| Current Liabilities | 5 M | ||||
About Merus BV Performance
Assessing Merus BV's fundamental ratios provides investors with valuable insights into Merus BV's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Merus BV is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 307.33 | 322.69 | |
| Return On Tangible Assets | (0.27) | (0.28) | |
| Return On Capital Employed | (0.38) | (0.36) | |
| Return On Assets | (0.26) | (0.28) | |
| Return On Equity | (0.32) | (0.34) |
Things to note about Merus BV performance evaluation
Checking the ongoing alerts about Merus BV for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Merus BV help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Merus BV appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 34.88 M. Net Loss for the year was (215.33 M) with profit before overhead, payroll, taxes, and interest of 20.94 M. | |
| Merus BV currently holds about 376.11 M in cash with (185.84 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.2. | |
| Merus BV has a frail financial position based on the latest SEC disclosures | |
| Over 98.0% of the company shares are owned by institutional investors | |
| Latest headline from news.google.com: Merus N.V. Shareholders to Vote on Genmab Acquisition Offer - TipRanks |
- Analyzing Merus BV's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Merus BV's stock is overvalued or undervalued compared to its peers.
- Examining Merus BV's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Merus BV's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Merus BV's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Merus BV's stock. These opinions can provide insight into Merus BV's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Merus Stock Analysis
When running Merus BV's price analysis, check to measure Merus BV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merus BV is operating at the current time. Most of Merus BV's value examination focuses on studying past and present price action to predict the probability of Merus BV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merus BV's price. Additionally, you may evaluate how the addition of Merus BV to your portfolios can decrease your overall portfolio volatility.